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The incidence of invasive fungal infections (IFIs) in 
critically ill patients has constantly increased over re-
cent decades, but their diagnosis still presents prob-
lems: conventional diagnostic (microscopic examina-
tion, fungal cultures) is sometimes insensitive, some 
procedures (e.g. tissue biopsy) require an aggressive 
approach not compatible with the critical condition of 
the patients, so the diagnosis is often based on clini-
cal suspicion or is made too late. Additional markers 
have been proposed in early diagnosis (mannan, galac-
tomannan, 1→3-beta-D-glucan antigen tests, specific 
antibodies or DNA fungal detection) but some of these 
still require further evaluation [1-5]. Recently, the role 
of procalcitonin (PCT) as a surrogate marker of fungal 
infections has been examined. Its quantitative evalua-
tion is considered a valid biological marker in different 
bacterial diseases[6-8] and it may distinguish bacter-
emia from non-infectious inflammatory conditions [9]. 
Regarding fungal infection, literature data are still few 
and controversial: some authors have reported that se-
rum PCT values are lower during fungal infection than 
in bacterial infection [10-12].
With the aim of evaluating the diagnostic usefulness of 
PCT in critically ill patients, we checked for the presence 
of PCT, compared to Candida mannan (CM), 1→3-beta-
D-glucan (BDG) and galactomannan (GM) antigens, in 
three different groups of patients, all with proven/prob-
able IFIs already diagnosed. Overall 20 subjects were 
investigated for serum PCT and circulating antigens at 
the same time of mycoses diagnosis: 8 neutropenic hae-
matologic adult patients (HAE: 7 suffering from acute 
myelogenic leukemia and 1 from acute lymphoblastic 
leukemia), 6 preterm infants hospitalized in Neonatal 
Intensive Care Unit (NICU: 4 very low birth weight and 
2 extremely low birth weight) and 6 patients admitted to 
the Intensive Care Unit (ICU: 4 previously exposed to 
abdominal surgical procedures and 2 to poly-trauma).
PCT values ranging from 0.5 to 1.0 ng/ml were con-
sidered moderately elevated, values > 1.0 ng/ml highly 
elevated. Regarding circulating antigens, samples were 
judged positive when levels of BDG were ≥ 80 pg/ml, 
CM ≥ 0.5 ng/ml, and GM when Index value was ≥ 0.5.
Our study has two main limitations: first, the small size 
of examined cases, because unsupported by statistical 
evaluation, might have hidden some differences between 
different groups with fungal disease; second, our analy-
sis was carried out in selected patients, excluding the 
cases of documented bacterial sepsis, in order to avoid 
other causes of a PCT increase.
In 8 HAE patients with fungal disease (5 pulmonary as-
pergillosis and 3 Candida blood stream infection (BSI), 2 
by Candida krusei and 1 by Candida parapsilosis), PCT 
value remained always very low (< 0.5 ng/ml); BDG and 
galactomannan tests were positive in patients with pul-
monary aspergillosis, while the patients with Candida 
parapsilosis/Candida krusei BSIs resulted negative for 
mannan and positive for the BDG test.
Among 6 NICU patients with BSIs caused by Candida 
albicans or Candida parapsilosis (3 cases respectively), 
PCT values were slightly increased in 4 cases (range 
0.55-1.27 ng/ml); one patient showed very high values 
(17.1 ng/ml) but a severe bacterial BSI was confirmed 
at the same time; while the PCT values resulted always 
< 0.5 ng/ml for another patient. In all 6 neonates with 
Candida BSI, the BDG test resulted positive at diagno-
sis, while the CM antigen resulted > 0.5 ng/ml only in 3 
patients with Candida albicans infection.
Among 6 ICU patients (5 with Candida albicans BSI 
and 1 with pulmonary aspergillosis), PCT values were 
very low (range 0.05-0.33 ng/ml) in the BSI patients; 
BDG and CM antigen were always positive. In contrast, 
the patient with aspergillosis showed a higher PCT value 
(1.91 ng/ml) and was BDG/GM positive.
Although it is known that PCT is also synthesized to 
some extent by leukocytes [13], some studies have 
shown that PCT may be an infection marker in neu-
tropenic patients [14-16]. Our data highlight low PCT 
levels in neutropenic haematologic patients, so its value 
might be underestimated.
In different adult patients, Petrikkos et al. [10] found 
PCT values lower in the early phase of IFIs. Besides, 
they report that the evaluation of mannan antigen in par-
allel may help to discriminate between invasive fungal 
and bacterial infections, especially in the case of Can-
dida albicans infection. Also Di Stefano [11] observed 
that PCT values are lower during fungal than in bacterial 
infection in preterm infants. Our data suggest that low or 
slightly increased PCT levels (HAE and NICU patients 
with Candida BSIs respectively), evaluated in tandem 
with circulating antigens (CM, GM, and BDG), could 
help to indicate fungal infection and expand the labora-
tory research.
In surgical patients with clinical signs of sepsis and risk 
factors for fungal infections, Martini et al. [12] consider 
a PCT value less than 2ng/ml as cut-off point to distin-
guish between sepsis due to Candida infection and sepsis 
of bacterial origin. In surgical patients with candidemia 
we found very low PCT levels (from 0.05 to 0.33 ng/
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ml) and higher values only in the patient suffering from 
aspergillosis (1.91 ng/ml).
In conclusion, our study suggests that PCT valuation 
in the serum of onco-haematologic or surgical patients, 
in contrast to circulating antigens, is not essential to di-
agnose a deep mycosis. The role of PCT in serum of 
critically ill patients depends on the population exam-
ined and its clinical setting. In fact, its valuation could 
be useful in premature infants being characterized by 
insufficiently specific symptoms. PCT values from 0.5 
to 1 ng/ml could focus the suspicion of an infectious 
process other than the bacterial sepsis and lead us to 
assess fungal circulating antigens to consider a fungal 
sepsis. Based on this observation, other studies on larger 
numbers of cases (especially in NICU patients) are war-
ranted to analyze the predictive value of PCT in fungal 
diseases.
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